intravitreal implant

Intravitreal implant could bring significant cost savings to NHS EnglandA study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Dexamethasone for DME shows stronger results compared with sham groupUse of an intravitreal implant for diabetic macular edema was more effective than a sham treatment across a variety of parameters in a subanalysis of the MEAD trial.
Dexamethasone for DME delivers long-term visual benefitsA dexamethasone implant provides long-term visual improvements in patients with diabetic macular edema treated with two doses of the drug.